<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02117453</url>
  </required_header>
  <id_info>
    <org_study_id>P120127</org_study_id>
    <secondary_id>2013-002531-15</secondary_id>
    <nct_id>NCT02117453</nct_id>
  </id_info>
  <brief_title>Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides</brief_title>
  <acronym>STATVAS</acronym>
  <official_title>Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether rosuvastatin could reduce the subclinical
      markers of atherosclerosis and the incidence of major cardiovascular events in patients with
      primary necrotizing vasculitides.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies demonstrated the presence of subclinical atherosclerosis in patients with
      ANCA-associated systemic necrotizing vasculitis. Since statins lower levels of inflammatory
      proteins and cholesterol, we hypothesized that people with ANCA-associated systemic
      necrotizing vasculitis but without indication for statin treatment according to
      recommandations might benefit from statin treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 27, 2014</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of change in mean carotid intima-media thickness for 6 predefined sites</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed with B-mode ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of change in mean carotid intima-media thickness for 6 predefined sites (distal common carotid arteries, carotid bulbs, internal carotid arteries), assessed with B-mode ultrasound</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed with B-mode ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in the number of plaques in three peripheral vessels (carotid and femoral arteries and abdominal aorta)</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed with B-mode ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in serum biomarkers of subclinical atherosclerosis</measure>
    <time_frame>24 months</time_frame>
    <description>ultra-sensitive CRP, VCAM-1, P-selectin, thrombomodulin, circulating endothelial, platelet and leucocytes microparticles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of major cardiovascular events (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in vasculitis activity</measure>
    <time_frame>24 months</time_frame>
    <description>BVAS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of vasculitis relapses</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in lipid profile (triglycerids, total, HDL and LDL cholesterol) compared to baseline value.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in endothelial function with brachial artery flow-mediated dilatation compared to baseline value</measure>
    <time_frame>24 months</time_frame>
    <description>endothelial function with brachial artery flow-mediated dilatation at months 6, 12 and 24 compared to baseline value, assessed with B-mode ultrasound in a subgroup of 66 patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>ANCA-associated Primary Necrotizing Vasculitides</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin 20 mg/day</description>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient &gt; 18 years. ANCA-associated vasculitis: granulomatosis with polyangiitis (GPA),
        microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA,
        Churg-Strauss syndrome).

        Patients will fulfill the Chapel Hill Consensus Criteria and the American College of
        Rheumatology criteria, in remission of vasculitis.

        Patients in remission of vasculitis after induction therapy (for first flare or relapse),
        including corticosteroids associated or not with immunosuppressive agents according to Good
        Clinical Practice for the treatment of vasculitis, between 6 months and 10 years after the
        beginning of induction therapy.

        Patients with informed and signed consent

        Exclusion Criteria:

        Other systemic vasculitis. Secondary vasculitis (paraneoplastic or infectious). Patient
        with active vasculitis after induction therapy, requiring salvage therapy.

        Inability to sign informed consent. Inability to take the experimental treatment.
        Hypersensitivity to rosuvastatin or to any of the excipients. Pregnancy. Chronic HCV, HBV
        and/or HIV infection. Patient receiving other statin or other hypolipemic agent. Patient
        requiring treatment with statin according to Afssaps recommandations published in 2005 as
        primary or secondary prevention.

        Subclinical atherosclerosis that confers a high cardiovascular risk before patient
        randomization :

          -  Carotid stenosis greater than 50% in diameter

          -  Ectasia of the abdominal aorta

          -  Intima-media thickening greater than 1.2 mm

          -  Diffuse atherosclerosis lesions

          -  Heterogeneous or hypoechoic prominent plaques greater than 2 mm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2014</study_first_submitted>
  <study_first_submitted_qc>April 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ANCA vasculitis</keyword>
  <keyword>Statin</keyword>
  <keyword>Subclinical markers of atherosclerosis</keyword>
  <keyword>Cardiovascular events</keyword>
  <keyword>Myocardial infarction</keyword>
  <keyword>Stroke</keyword>
  <keyword>Arterial revascularization</keyword>
  <keyword>Unstable angina</keyword>
  <keyword>Death</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

